Chongyang Huang, Yanru Liu, Jiangang Zhang, Sheng Guan, Tao Quan, Zhen Chen, Xiaojie Fu, Sen Wei, Kaihao Han, Xiaoan Zhou, Chengcheng Zhu, Edgar Samaniego, Yueqi Zhu, Haowen Xu
{"title":"机械取栓治疗符合TRACE-III条件的缺血性卒中患者:一项与TRACE-III和TIMELESS试验比较的多中心回顾性研究","authors":"Chongyang Huang, Yanru Liu, Jiangang Zhang, Sheng Guan, Tao Quan, Zhen Chen, Xiaojie Fu, Sen Wei, Kaihao Han, Xiaoan Zhou, Chengcheng Zhu, Edgar Samaniego, Yueqi Zhu, Haowen Xu","doi":"10.1002/acn3.70107","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The results of the TRACE-III trial demonstrated that tenecteplase (TNK) might be comparable to TNK combined with mechanical thrombectomy (MT) for large vessel occlusion (LVO) stroke within 4.5 to 24 h of onset, as tested in the TIMELESS trial. We aimed to evaluate the safety and effectiveness of MT alone in TRACE-III-eligible patients in routine clinical settings, comparing the results of both trials.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective multicenter cohort study involved consecutive patients who underwent MT alone at three stroke centers between March 2021 and July 2024. Only those meeting the inclusion and exclusion criteria of TRACE-III were included. Safety, clinical, and imaging outcomes were compared with the TRACE-III and TIMELESS trial data.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>336 TRACE-III-eligible patients were enrolled in our cohort. MT alone had a higher percentage of patients with a modified Rankin scale (mRS) score of 0–2 at 90 days (58.9%) compared to the TNK group in TRACE-III, TNK and placebo groups in TIMELESS (43.6%, 46.0%, and 42.4%, respectively; all <i>p</i> < 0.01). Additionally, MT achieved a higher rate of early-stage reperfusion (86.0%) compared to the TRACE-III TNK, TIMELESS TNK, and TIMELESS placebo groups (27.9%, 76.7%, and 63.9%; all <i>p</i> < 0.05). The mRS 0–1 at 90 days, incidence of symptomatic intracerebral hemorrhage, and mortality at 90 days were 36.0%, 5.4%, and 14.9%, respectively, similar to those in the three groups (all <i>p</i> > 0.05).</p>\n </section>\n \n <section>\n \n <h3> Interpretation</h3>\n \n <p>In clinical practice, MT can achieve higher rate of early-stage reperfusion and tended to yield better functional outcomes than intravenous TNK, with similar safety, in TRACE-III-eligible patients.</p>\n </section>\n </div>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":"12 9","pages":"1886-1893"},"PeriodicalIF":3.9000,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.70107","citationCount":"0","resultStr":"{\"title\":\"Mechanical Thrombectomy for TRACE-III-Eligible Patients With Ischemic Stroke: A Multicenter Retrospective Study Compared to TRACE-III and TIMELESS Trials\",\"authors\":\"Chongyang Huang, Yanru Liu, Jiangang Zhang, Sheng Guan, Tao Quan, Zhen Chen, Xiaojie Fu, Sen Wei, Kaihao Han, Xiaoan Zhou, Chengcheng Zhu, Edgar Samaniego, Yueqi Zhu, Haowen Xu\",\"doi\":\"10.1002/acn3.70107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>The results of the TRACE-III trial demonstrated that tenecteplase (TNK) might be comparable to TNK combined with mechanical thrombectomy (MT) for large vessel occlusion (LVO) stroke within 4.5 to 24 h of onset, as tested in the TIMELESS trial. We aimed to evaluate the safety and effectiveness of MT alone in TRACE-III-eligible patients in routine clinical settings, comparing the results of both trials.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This retrospective multicenter cohort study involved consecutive patients who underwent MT alone at three stroke centers between March 2021 and July 2024. Only those meeting the inclusion and exclusion criteria of TRACE-III were included. Safety, clinical, and imaging outcomes were compared with the TRACE-III and TIMELESS trial data.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>336 TRACE-III-eligible patients were enrolled in our cohort. MT alone had a higher percentage of patients with a modified Rankin scale (mRS) score of 0–2 at 90 days (58.9%) compared to the TNK group in TRACE-III, TNK and placebo groups in TIMELESS (43.6%, 46.0%, and 42.4%, respectively; all <i>p</i> < 0.01). Additionally, MT achieved a higher rate of early-stage reperfusion (86.0%) compared to the TRACE-III TNK, TIMELESS TNK, and TIMELESS placebo groups (27.9%, 76.7%, and 63.9%; all <i>p</i> < 0.05). The mRS 0–1 at 90 days, incidence of symptomatic intracerebral hemorrhage, and mortality at 90 days were 36.0%, 5.4%, and 14.9%, respectively, similar to those in the three groups (all <i>p</i> > 0.05).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Interpretation</h3>\\n \\n <p>In clinical practice, MT can achieve higher rate of early-stage reperfusion and tended to yield better functional outcomes than intravenous TNK, with similar safety, in TRACE-III-eligible patients.</p>\\n </section>\\n </div>\",\"PeriodicalId\":126,\"journal\":{\"name\":\"Annals of Clinical and Translational Neurology\",\"volume\":\"12 9\",\"pages\":\"1886-1893\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.70107\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Clinical and Translational Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acn3.70107\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Translational Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acn3.70107","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Mechanical Thrombectomy for TRACE-III-Eligible Patients With Ischemic Stroke: A Multicenter Retrospective Study Compared to TRACE-III and TIMELESS Trials
Objective
The results of the TRACE-III trial demonstrated that tenecteplase (TNK) might be comparable to TNK combined with mechanical thrombectomy (MT) for large vessel occlusion (LVO) stroke within 4.5 to 24 h of onset, as tested in the TIMELESS trial. We aimed to evaluate the safety and effectiveness of MT alone in TRACE-III-eligible patients in routine clinical settings, comparing the results of both trials.
Methods
This retrospective multicenter cohort study involved consecutive patients who underwent MT alone at three stroke centers between March 2021 and July 2024. Only those meeting the inclusion and exclusion criteria of TRACE-III were included. Safety, clinical, and imaging outcomes were compared with the TRACE-III and TIMELESS trial data.
Results
336 TRACE-III-eligible patients were enrolled in our cohort. MT alone had a higher percentage of patients with a modified Rankin scale (mRS) score of 0–2 at 90 days (58.9%) compared to the TNK group in TRACE-III, TNK and placebo groups in TIMELESS (43.6%, 46.0%, and 42.4%, respectively; all p < 0.01). Additionally, MT achieved a higher rate of early-stage reperfusion (86.0%) compared to the TRACE-III TNK, TIMELESS TNK, and TIMELESS placebo groups (27.9%, 76.7%, and 63.9%; all p < 0.05). The mRS 0–1 at 90 days, incidence of symptomatic intracerebral hemorrhage, and mortality at 90 days were 36.0%, 5.4%, and 14.9%, respectively, similar to those in the three groups (all p > 0.05).
Interpretation
In clinical practice, MT can achieve higher rate of early-stage reperfusion and tended to yield better functional outcomes than intravenous TNK, with similar safety, in TRACE-III-eligible patients.
期刊介绍:
Annals of Clinical and Translational Neurology is a peer-reviewed journal for rapid dissemination of high-quality research related to all areas of neurology. The journal publishes original research and scholarly reviews focused on the mechanisms and treatments of diseases of the nervous system; high-impact topics in neurologic education; and other topics of interest to the clinical neuroscience community.